Drug Trial Radar · NCT03248492
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
253
Actual
Start
Aug 25, 2017
Primary completion
Mar 21, 2019
Study completion May 6, 2024
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca; Daiichi Sankyo Co., Ltd.
- First posted
- Aug 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.
Conditions
- Breast Cancer
Interventions
DS-8201aDrug
DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate as Confirmed by Independent Central Review Following Intravenous Administration of 5.4 mg/kg DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)
Locations
99 sites in 9 countries. Site status is shown where the registry gives one.
Alaska Urological Institute dba Alaska Clinical Research Center
Anchorage, Alaska
Arizona Oncology Associates
Tucson, Arizona
The Regents of the University of California
Los Angeles, California
Sharp Clinical Oncology Research
San Diego, California
University of California San Francisco
San Francisco, California
Sansum Clinic
Santa Barbara, California
Innovative Clinical Research Institute, LLC
Whittier, California
Sylvester Comprehensive Cancer Center - Deerfield Beach
Boca Raton, Florida
Specialist Global Research
Hialeah, Florida
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida
Piedmont Cancer Institute
Atlanta, Georgia
Straub Medical Center
Honolulu, Hawaii
University of Hawaii
Honolulu, Hawaii
Norton Healthcare
Louisville, Kentucky
University of Louisville Research Foundation
Louisville, Kentucky
Ochsner Clinic Foundation
New Orleans, Louisiana
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists
East Setauket, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Aultman Hospital Cancer Center
Canton, Ohio
University of Cincinnati Medical Center
Cincinnati, Ohio
Allegheny General Hospital
Pittsburgh, Pennsylvania
UPMC Cancer Center
Pittsburgh, Pennsylvania
St Francis Hospital
Greenville, South Carolina
Accurate Clinical Research
Baytown, Texas
Texas Oncology, P.A.
Dallas, Texas
Texas Oncology - Memorial City
Houston, Texas
MD Anderson Cancer Center
Houston, Texas
The Methodist Hospital Research Institute
Houston, Texas
Texas Oncology, P.A. - Longview
Tyler, Texas
The University of Texas Health Science Center at Tyler
Tyler, Texas
Virginia Cancer Specialists, PC
Fairfax, Virginia
Providence Regional Medical Center - Everett
Everett, Washington
Imeldaziekenhuis
Bonheiden, Belgium
Grand Hôpital de Charleroi
Charleroi, Belgium
UZ Leuven
Leuven, Belgium
CHU Sart Tilman
Liège, Belgium
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.